Log in to search using one of your social media accounts:

 

Positron Emission Tomography-Based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin Lymphoma
• High metabolic tumor volume predicts poor post-autograft survival in Hodgkin lymphoma.• Quantitative tumor parameters may improve the predictive power of pre-transplant PET for patients with residual tumor. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 20, 2017 Category: Hematology Authors: V ít Procházka, Rakhee S. Gawande, Zuzan Cayci, Jerry W. Froelich, Qing Cao, Chris Wilke, Kathryn Dusenbery, Daniel J. Weisdorf, Veronika Bachanova Source Type: research

HLA-Haploidentical Stem Cell Transplant with Pre-Transplant Immunosuppression for Patients with Sickle Cell Disease
• Stem cell transplant can offer a cure for patients with sickle cell disease (SCD)• SCD patients often lack suitable stem cell donors and have high rate of graft failure• Successful haploidentical transplant significantly expands the donor pool for SCD• PTIS with a reduced toxicity regimen provides prompt engraftment and low toxicity (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2017 Category: Hematology Authors: Anna B. Pawlowska, Jerry C. Cheng, Nicole A. Karras, Weili Sun, Leo D. Wang, Alison D. Bell, Lisa Gutierrez, Joseph Rosenthal Source Type: research

Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplant (HCT) for Acute Myeloid Leukemia and Myelodysplasia: Clinically Relevant Time-Points and 100 Copies Threshold Value
• WT1 levels in bone marrow before and after HCT provide relevant prognostic information. WT1 levels at leukocyte recovery may be helpful to plan therapeutic strategies. Sustained bone marrow WT1 levels below 100 copies are associated with a favorable outcome. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2017 Category: Hematology Authors: Josep F. Nomded éu, Albert Esquirol, Maite Carricondo, Marta Pratcorona, Montserrat Hoyos, Ana Garrido, Miguel Rubio, Elena Bussaglia, Irene García-Cadenas, Camino Estivill, Salut Brunet, Rodrigo Martino, Jorge Sierra Source Type: research

Outcome and Minimal Residual Disease Monitoring in t(16;21) Acute Myeloid Leukemia Patients Receiving Allogeneic Hematologic Stem Cell Transplantation
• t(16;21) AML is an indication for allo-HSCT.• The TLS-ERG transcript levels reflected MRD and may predict relapse after HSCT.• The TLS-ERG transcript levels might guide effective intervention. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2017 Category: Hematology Authors: Ya-Zhen Qin, Yao Chen, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Huan Chen, Xiao-Su Zhao, Kai-Yan Liu, Xiao-Jun Huang Source Type: research

Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review From the Late Effects and Quality of Life Working Committee of the CIBMTR and Complications and Quality of Life Working Party of the EBMT
• Understanding neurocognitive dysfunction of HCT is evolving• Standardization of how to define and assess neurocognitive dysfunction is needed• Future neurocognitive dysfunction research is needed among diverse HCT populations• HCT neurocognitive dysfunction assessment and treatment are not well elucidated• More research is needed to accurately characterize neurocognitive dysfunction (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2017 Category: Hematology Authors: Debra Lynch Kelly, David Buchbinder, Rafael F. Duarte, Jeffrey J. Auletta, Neel Bhatt, Michael Byrne, Melissa Gabriel, Anuj Mahindra, Maxim Norkin, Helene Schoemans, Ami J. Shah, Ibrahim Ahmed, Yoshiko Atsuta, Grzegorz W. Basak, Sara Beattie, Sita Bhella, Source Type: research

Combination of High-Dose Methylprednisolone and Defibrotide for Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplant Recipients
• Addition of high-dose steroids to defibrotide improves VOD response after HSCT• Addition of high-dose steroids to defibrotide in patients with VOD improves OS• Brief high-dose steroid pulse is beneficial and low risk therapy for VOD (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2017 Category: Hematology Authors: Nicholas J. Gloude, Sonata Jodele, Ashley Teusink-Cross, Michael Grimley, Stella M. Davies, Adam Lane, Kasiani C. Myers Source Type: research

Maintenance Rituximab after High-Dose Therapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma, which is characterized by early dissemination and an unfavorable clinical course. Treatment with conventional chemotherapy resulted in unsatisfactory outcomes and a median survival of less than 3 years after diagnosis of MCL [1]. During recent years, the prognosis of patients with MCL has improved considerably and the refinement of dose-intensified approaches such as autologous stem-cell transplantation (ASCT) has contributed significantly to this development. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2017 Category: Hematology Authors: Tobias Roider, Sascha Dietrich Source Type: research

Choosing the Alternative
Since the initial demonstration of the fundamental impact of HLA compatibility in dictating the outcome of allogeneic hematopoietic stem cell transplantation (HSCT), efforts from the worldwide transplant community have been focused on two challenging and somewhat contradictory tasks: on the one hand, increasing the pool of volunteer stem cell donors to raise the chance of finding an acceptable match for patients in need of a transplant, and on the other hand, devising strategies to improve the feasibility and safety of HSCT from partially HLA-incompatible donors for all those patients that still do not find a match. (Sourc...
Source: Biology of Blood and Marrow Transplantation - September 19, 2017 Category: Hematology Authors: Luca Vago, Fabio Ciceri Source Type: research

Masthead (Purpose and Scope)
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 16, 2017 Category: Hematology Source Type: research

Editorial Board
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 16, 2017 Category: Hematology Source Type: research

Officers and Directors of ASBMT
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 16, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 16, 2017 Category: Hematology Source Type: research

ASBMT Notes
The annual American Society for Blood and Marrow Transplantation (ASBMT) Clinical Research Training Course was held July 12 to 17 in Charlotte, North Carolina, for 12 scholars and 10 faculty members from across the transplant spectrum. This course was developed in response to concerns that clinical fellowship programs do not always adequately cover the principles of research and how to take findings from the laboratory to the clinic. From across North America, the best and brightest transplant fellows and junior faculty involved in clinical research gathered together to be nurtured and cultivated to ensure their own person...
Source: Biology of Blood and Marrow Transplantation - September 16, 2017 Category: Hematology Source Type: research

Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
Allogeneic stem cell transplant (ASCT) with HLA matched donors is increasingly used for older patients with AML/MDS. It remains unclear if haploidentical transplantation (haploSCT) is a suitable option for older patients with this disease. We analyzed 43 patients with AML/MDS (median age 61 years) who underwent a haploSCT at our institution. All the patients received a fludarabine-melphalan-based reduced-intensity conditioning regimen and post-transplant cyclophosphamide-based GVHD prophylaxis. Except one patient who had early death, the remaining 42 patients (98%) engrafted donor cells. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 13, 2017 Category: Hematology Authors: Stefan O. Ciurea, Mithun V. Shah, Rima M. Saliba, Sameh Gaballa, Piyanuch Kongtim, Gabriela Rondon, Julianne Chen, Whitney Wallis, Kai Cao, Marina Konopleva, Naval Daver, Jorge Cortes, Farhad Ravandi, Amin Alousi, Sairah Ahmed, Uday Popat, Simrit Parmar, Source Type: research

Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplant Recipients 50 Years or Older
• We retrospectively analyzed 1607 patients who underwent allo-HCT using FB2, FB4 or FM140.• The incidences of NRM in FB4 and FM140 were higher than that in FB2.• The relapse rates in FB4 and FM140 were lower than that in FB2.• There were no significant differences in OS among the FB2, FB4, and FM140 groups. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 7, 2017 Category: Hematology Authors: Koji Kawamura, Shinichi Kako, Shuichi Mizuta, Ken Ishiyama, Jun Aoki, Shingo Yano, Takahiro Fukuda, Naoyuki Uchida, Yukiyasu Ozawa, Tetsuya Eto, Koji Iwato, Heiwa Kanamori, Kaoru Kahata, Tadakazu Kondo, Masashi Sawa, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshi Source Type: research

Improving the Informed Consent Process in Hematopoietic Cell Transplantation: Patient, Caregiver, and Provider Perspectives
• Important information to clinical research participants includes benefits to others• There is a need for increasing patient engagement during informed consent process• Multiple perspectives on important information for the informed consent process (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 4, 2017 Category: Hematology Authors: Minakshi Raj, Sung Won Choi, Tuba Suzer Gurtekin, Jodyn Platt Source Type: research

Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence Following Hematopoietic Cell Transplantation for Sickle Cell Disease
• Mixed chimerism is more common after reduced intensity conditioning regimens• Primary graft failure occurred exclusively after reduced intensity conditioning regimens• Donor chimerism>25% or hemoglobin S (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 4, 2017 Category: Hematology Authors: Allistair Abraham, Matthew Hsieh, Mary Eapen, Courtney Fitzhugh, Jeanette Carreras, Daniel Kessler, Gregory Guilcher, Naynesh Kamani, Mark C. Walters, Jaap J. Boelens, John Tisdale, Shalini Shenoy, National Institutes of Health, Center for International B Source Type: research

The Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation
• We evaluated all high-grade toxicities in 1-year survivors of CD34+- selected allo-HCT.• HCT-CI ≥ 3 and GVHD in the 1st year resulted in more late toxicities, late NRM, and poorer OS.• Limiting toxicities in the 1st year and identifying those at risk for late toxicity may improve outcomes. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 1, 2017 Category: Hematology Authors: Michael Scordo, Gunjan L. Shah, Satyajit Kosuri, Diego Adrianzen Herrera, Christina Cho, Sean M. Devlin, Molly A. Maloy, Jimmy Nieves, Taylor Borrill, Scott T. Avecilla, Richard C. Meagher, Dean C. Carlow, Richard J. O'Reilly, Esperanza B. Papadopoulos, A Source Type: research

Ethical Challenges in Hematopoietic Cell Transplantation for Sickle Cell Disease: a Review
• Liberal eligibility for SCD matched sibling HCT does not violate ethical principles.• Deferring HCT in childhood until patients can consent is not ethically preferable.• Not offering HCT due to psychosocial concerns may be appropriate.• Minors can serve as donors if necessary safeguards ar e respected.• Preimplantation genetic diagnosis to conceive a matched sibling is an ethical option. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 1, 2017 Category: Hematology Authors: Robert Sheppard Nickel, Naynesh R. Kamani Source Type: research

Consensus Report by PALISI and PBMTC Joint Working Committees, Supportive Care Guidelines for Management of VOD in Children and Adolescents; Part 3: Focus on Cardio-Respiratory Dysfunction, Infections, Liver Dysfunction and Delirium
• This Part 3 of the consensus report by PALISI and PBMTC provides evidence based guidelines for the supportive care of children with VOD who develop multiple organ dysfunctions.• The roles of non-invasive ventilation, invasive ventilation and high level cardiac output monitoring strategies are discussed.• Infection related issues in patients with VOD are discussed.• Guidelines for the treatment of fulminant hepatic failure and hepatic encephalopathy are provided.• Strategies to prevent and treatment of delirium in children with VOD is discussed. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 1, 2017 Category: Hematology Authors: Nadia Ovchinsky, Warren Frazier, Jeffery J. Auletta, Christopher C. Dvorak, Monica Ardura, Enkyung Song, Jennifer McArthur, Asumthia Jeyapalan, Robert Tamburro, Kris M. Mahadeo, Chani Traube, Christine N. Duncan, Rajinder P.S. Bajwa Source Type: research

Outcome Analysis of Pediatric ALL Patients Treated with TBI-Free Allogeneic Hematopoietic Stem Cell Transplantation: Comparison of Patients with and Without Central Nervous System Involvement
• Younger acute lymphoblastic leukemia (ALL) patients were at increased risk for CNS involvement.• Allogeneic hematopoietic stem cell transplantation (HSCT) using a non-total body irradiation (TBI) conditioning regimen led to similar early and long-term outcomes for pediatric ALL patients with a nd without central nervous system (CNS) involvement.• Having similar results compared with other studies using a TBI-based allogeneic HSCT on ALL patients with CNS involvement, a TBI-free allogeneic HSCT seems to be feasible and effective for CNS involved ALL patients. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 1, 2017 Category: Hematology Authors: Amir Ali Hamidieh, Seyed Mostafa Monzavi, Maryam Kaboutari, Maryam Behfar, Mohsen Esfandbod Source Type: research

Recovery of Pulmonary Function after Allogeneic Hematopoietic Cell Transplantation in Children is Associated with Improved Survival
1. Normalization of lung function is possible in survivors of allogeneic hematopoietic cell transplantation.2. Patients who recovered lung function had similar overall survival to those who had normal lung function post-transplant.3. Pulmonary complications and pre-transplant forced vital capacity z-scores were associated with recovery of lung function.4. Strategies to decrease pulmonary complications may improve outcome. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 30, 2017 Category: Hematology Authors: Ashok Srinivasan, Anusha Sunkara, William Mitchell, Sudeep Sunthankar, Guolian Kang, Dennis C. Stokes, Saumini Srinivasan Source Type: research

Haploidentical Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome
1 CIBMTR scoring system can predict long-term outcomes of MDS following haplo-HSCT.2 We refined this scoring system and proposed a new one for haplo-HSCT recipients.3 Our refined scoring system can predict short- and long-term outcomes after haplo-HSCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 30, 2017 Category: Hematology Authors: Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang Source Type: research

High Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease
• HDM/SCT is valuable for selected patients with AL amyloidosis and MIDD associated ESRD• 5-year OS was 54% and associated with achievement of CR after HDM/SCT• Treatment-related mortality occurred in 8% of patients• Common grade 3/4 non-hematologic toxicities were infections, mucositis and pulmonary complications (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 30, 2017 Category: Hematology Authors: Felipe Batalini, Laura Econimo, Karen Quillen, J. Mark Sloan, Shayna Sarosiek, Dina Brauneis, Andrea Havasi, Lauren Stern, Laura Dember, Vaishali Sanchorawala Source Type: research

Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network Meta-Analysis
First Network analysis for different brands of ATG as GVHD prophylaxis indicates • different brands have different effect• no increased risk of relapse (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 29, 2017 Category: Hematology Authors: Nico Gagelmann, Francis Ayuk, Christine Wolschke, Nicolaus Kr öger Source Type: research

Adjuvant Peptide Pulsed Dendritic Cell Vaccination in Addition to T Cell Adoptive Immunotherapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
Adjuvant CMV peptide DC vaccination in addition to donor-derived CMV peptide specific T cell infusion appears to be feasibleNo immediate adverse reactions were noted on DC vaccination or T cell infusion1 of 4 patients developed grade III acute GVHD post DC vaccination and T cell infusionAll patients who received DC vaccination and CMV specific T cell infusion demonstrated immune reconstitution against CMV (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 29, 2017 Category: Hematology Authors: Chun K.K.Ma, Leighton Clancy, Renee Simms, Jane Burgess, Shivashni Deo, Emily Blyth, Kenneth P. Micklethwaite, David J. Gottlieb Source Type: research

Optimizing Anti-Thymocyte Globulin Dosing for Unrelated Donor Allogeneic Hematopoietic Cell Transplant Based on Recipient Absolute Lymphocyte Count
• Current dosing of anti-thymocyte globulin (ATG) is weight-based and empiric• A primary target of ATG, the recipient lymphocyte, is not based on recipient weight• ATG interacts with the recipient lymphocyte count to predict transplant outcomes• Higher ATG doses are associated with increased infectious complications and less severe chronic GVHD (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 29, 2017 Category: Hematology Authors: Vanessa E. Kennedy, Heidi Chen, Bipin N. Savani, John Greer, Adetola A. Kassim, Brian G. Engelhardt, Stacey Goodman, Salyka Sengsayadeth, Wichai Chinratanalab, Madan Jagasia Source Type: research

Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation (HCT): a Single Center Analysis of 613 Adult HCT Recipients Using a Modified Composite Endpoint
• Modified m-GRFS is a more objective endpoint of survival and quality of life after allogeneic HCT.• Only one third of HCT recipients meet the m-GRFS endpoint.• Factors predicting m-GRFS include donor type, donor-recipient sex match and disease risk.• Recipients of MRD and HID transplants u sing mostly PBSC graft source have a better m-GRFS compared to MUD (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 29, 2017 Category: Hematology Authors: Melhem Solh, Xu Zhang, Katelin Connor, Stacey Brown, Lawrence E. Morris, H. Kent Holland, Asad Bashey, Scott R. Solomon Source Type: research

Pre-Engraftment Bloodstream Infections after Allogeneic Hematopoietic Cell Transplantation: Impact of T Cell-Replete Transplantation from a Haploidentical Donor
Bloodstream infection (BSI) is an important complication in hematopoietic cell transplantation (HCT) recipients, particularly during the pre-engraftment neutropenia [1-3]. BSI affects between 16% and 40% of patients [1-8], with an associated mortality ranging from (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 28, 2017 Category: Hematology Authors: Malgorzata Mikulska, Anna Maria Raiola, Federica Galaverna, Elisa Balletto, Maria Lucia Borghesi, Riccardo Varaldo, Francesca Gualandi, Livia Giannoni, Giordana Pastori, Daniele Roberto Giacobbe, Alessio Signori, Valerio Del Bono, Claudio Viscoli, Andrea Source Type: research

Immune-Mediated Hematopoietic Failure after Allogeneic Hematopoietic Stem Cell Transplantation: a Common Cause of Late Graft Failure in Patients with Complete Donor Chimerism
• PNH-type cells and HLA-allele lacking leukocytes were detected in patients with LGF• Two patients with PNH-type cells achieved transfusion independence after ATG therapy• Immune mechanisms similar to AA underlie half of the patients with donor-type LGF (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 28, 2017 Category: Hematology Authors: Kana Maruyama, Nobuyuki Aotsuka, Yoshihisa Kumano, Naoko Sato, Naomi Kawashima, Yoshiyuki Onda, Hiroyuki Maruyama, Takamasa Katagiri, Yoshitaka Zaimoku, Noriharu Nakagawa, Kazuyoshi Hosomichi, Seishi Ogawa, Shinji Nakao Source Type: research

Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation – a Comparison of Eculizumab Therapy and Conventional Therapy
We report the results of a single center analysis of a cohort of 39 patients treated between 1997 and 2016 for transplantion –associated thrombotic microangiopathy. We evaluated two subgroups of patients: 24 patients treated between 1997 and 2014 who received conventional therapy and 15 patients who were treated with the complement–inhibiting monoclonal antibody eculizumab between 2014 and 2016. The conventional thera py group was predominantly treated with defibrotide alone or in combination with plasmapheresis or rituximab. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 28, 2017 Category: Hematology Authors: Stephan R Bohl, Florian Kuchenbauer, Stefanie von Harsdorf, Nadine Kloevekorn, Stefan S Sch önsteiner, Arefeh Rouhi, Phyllis Schwarzwälder, Hartmut Döhner, Donald Bunjes, Martin Bommer Source Type: research

Pre-Engraftment Bloodstream Infections after Allogeneic Hematopoietic Cell Transplantation: the Impact of T-Repleted Transplant From Haploidentical Donors.
• Pre-engraftment bloodstream infections (BSI) affected 30% of allogenic HCT recipients• The risk was the highest in case of T-repleted haploidentical transplants• Gram-negative BSI, particularly if carbapenem-resistant, had negative impact on survival (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 28, 2017 Category: Hematology Authors: Malgorzata Mikulska, Anna Maria Raiola, Federica Galaverna, Elisa Balletto, Maria Lucia Borghesi, Riccardo Varaldo, Francesca Gualandi, Livia Giannoni, Giordana Pastori, Daniele Roberto Giacobbe, Alessio Signori, Valerio Del Bono, Claudio Viscoli, Andrea Source Type: research

Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
Diffuse large B cell lymphoma (DLBCL) consists of at least 3 distinct molecular subtypes based on its cell of origin (COO): the activated B cell –like (ABC), the germinal center B cell–like (GCB), and primary mediastinal B cell–like subtypes [1]. Of these, the non-GCB subtype, generally classified by immunohistochemical staining and consisting predominantly of the ABC subtype, carries worse prognosis than the GCB subtype because of its resistance to CHOP-like chemotherapy regimens [2-4]. To improve patient outcome, therapeutic strategies targeting the known pathobiology of ABC DLBCL, specifically constitu...
Source: Biology of Blood and Marrow Transplantation - August 25, 2017 Category: Hematology Authors: Yi-Shan Lee, Jingxia Liu, Kristine A. Fricano, Erika M. Webb, Dan R. Toolsie, Sara Jones, James A. Rhoads, Ravi Vij, Amanda F. Cashen, Camille N. Abboud, Peter Westervelt, Nancy L. Bartlett, John F. Dipersio, Friederike H. Kreisel, Kian-Huat Lim Source Type: research

Johannes Joseph van Rood, Transplantation Pioneer (April 7, 1926, to July 21, 2017)
Jon van Rood, as he was usually known with typical Dutch informality, was a pioneer in hematopoietic cell transplantation and in defining the HLA system in humans. I liked to call him along with late Professor Dirk van Bekkum the “double dutch” (a term given to the complex and challenging sport of jumping within 2 ropes on seeing it played by Dutch children when the English arrived in New Holland [New York] in 1664). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 25, 2017 Category: Hematology Authors: Robert Peter Gale Source Type: research

Lack of Prognostic Impact of MyD88 L265P Mutation for DLBCL Patients Undergoing Autologous Stem Cell Transplantation
• The MyD88 L265P mutation is not associated with post-ASCT progression-free or overall survival for DLBCL.• Patients with non-GCB DLBCL have significantly worse overall survival from initial diagnosis and after ASCT.• The International Prognostic Index remains the most reliable prognostic too l for DLBCL patients undergoing ASCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 25, 2017 Category: Hematology Authors: Yi-Shan Lee, Jingxia Liu, Kristine A. Fricano, Erika M. Webb, Dan R. Toolsie, Sara Jones, James A. Rhoads, Ravi Vij, Amanda F. Cashen, Camille N. Abboud, Peter Westervelt, Nancy L. Bartlett, John F. Dipersio, Friederike H. Kreisel, Kian-Huat Lim Source Type: research

Johannes Joseph Van Rood Transplant Pioneer (April 7, 1926-July 21, 2017)
Jon van Rood, as he was usually known with typical Dutch informality, was a pioneer in haematopoietic cell transplantation and in defining the HLA-system in humans. I liked to call him, along with late Prof. Dirk van Bekkum, the Double Dutch (a term given to the complex and challenging sport of jumping within two ropes on seeing it played by Dutch children when the English arrived in New Holland [New York] in 1664). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 25, 2017 Category: Hematology Authors: Robert Peter Gale Source Type: research

Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes
The Common Terminology Criteria for Adverse Events (CTCAE) is a set of standardized criteria for the classification of adverse effects of medications or interventions used during cancer therapy [1-3]. Many clinical trials, now extending beyond oncology, encode their observations according to the CTCAE system; however, the CTCAE does not encompass all potential adverse events and was not designed for high-dose chemotherapy regimens. Allogeneic hematopoietic cell transplantation (AHSCT) is a well-established treatment for a variety of malignant and nonmalignant hematologic disorders [4]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 24, 2017 Category: Hematology Authors: Gabriela Rond ón, Rima M. Saliba, Julianne Chen, Celina Ledesma, Amin M. Alousi, Betul Oran, Chitra M. Hosing, Partow Kebriaei, Issa F. Khouri, Elizabeth J. Shpall, Uday R. Popat, Richard E. Champlin, Stefan O. Ciurea Source Type: research

Matrix Metalloproteinase-9 in Monocytic Myeloid-Derived Suppressor Cells Correlate with Early Infections and Clinical Outcomes in Allogeneic Hematopoietic Stem Cell Transplantation
• Monocytic-MDSCs but not granulocytic-MDSCs affect clinical outcomes.• Monocytic-MDSCs more abundantly produced matrix metalloproteinase-9 (MMP-9).• Monocytic-MDSCs suppress T cells via MMP-9.• MMP-9 levels correlated with the occurrence of infections and transplant outcomes. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 24, 2017 Category: Hematology Authors: Sung-Eun Lee, Ji-Young Lim, Tae Woo Kim, Young-Woo Jeon, Jae-Ho Yoon, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Woo-Sung Min, Dong-Mi Shin, Eun Young Choi, Chang-Ki Min Source Type: research

Outcome of Second Transplantation Using Umbilical Cord Blood for Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia
• Graft failure after transplant remains a serious problem in aplastic anemia.• Second cord blood transplant is an option for graft failure in aplastic anemia.• Fludarabine plus low-dose TBI-based conditioning tend to show better survival.• Mycofenolate mofetil-containing GVHD prophylaxis ma y improve engraftment rate. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 24, 2017 Category: Hematology Authors: Yasushi Onishi, Takehiko Mori, Shinichi Kako, Hideo Koh, Naoyuki Uchida, Tadakazu Kondo, Takeshi Kobayashi, Hiromasa Yabe, Toshihiro Miyamoto, Koji Kato, Ritsuro Suzuki, Shinji Nakao, Hirohito Yamazaki, on behalf of the adult aplastic anemia working group Source Type: research

Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem-Cell Transplant Outcomes
Fluid overload (FO) is commonly seen during hospitalization for allogeneic hematopoietic stem-cell transplantation (AHSCT). We hypothesized that FO is associated with transplant outcomes and evaluated this complication in two cohorts of patients and graded based on post-transplant weight gain, symptoms, and need for treatment, and was scored in real time by an independent team. The first cohort (study cohort) underwent haploidentical transplantation for hematologic malignancies (N=145) following a melphalan-based conditioning regimen. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 24, 2017 Category: Hematology Authors: Gabriela Rond ón, Rima M. Saliba, Julianne Chen, Celina Ledesma, Amin M. Alousi, Betul Oran, Chitra M. Hosing, Partow Kebriaei, Issa F. Khouri, Elizabeth J. Shpall, Uday R. Popat, Richard E. Champlin, Stefan O. Ciurea Source Type: research

Is It All About Age or Personalized Haploidentical Hematopoietic Stem Cell Transplantation for Elderly Patients?
The number of allogeneic hematopoietic stem cell transplantations (allo-HCTs) performed each year with curative intent for older adults with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) has continued to rise over the past decade. Much of the progress in the use of allo-HCT in older adults is due to the use of reduced-intensity conditioning (RIC) regimens, which have allowed many older patients with AML or MDS to receive curative allo-HCT [1]. Without RIC, these older patients would otherwise be unfit for allo-HCT because of the toxicity associated with myeloablative conditioning regimens. (Source: Bio...
Source: Biology of Blood and Marrow Transplantation - August 22, 2017 Category: Hematology Authors: Nelli Bejanyan Source Type: research

Is It All About Age or Personalized Haplo HCT for Elderly?
The number of allogeneic transplants performed each year with curative intent for older adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) continued to rise during the past decade. Much of the progress in the use of alloHCT in older adults is due to reduced-intensity conditioning (RIC) regimens, which have allowed many older patients with AML or MDS to receive curative allogeneic hematopoietic cell transplantation (alloHCT).1 Without RIC, these older patients would otherwise be unfit for alloHCT because of the toxicities of myeloablative conditioning. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 22, 2017 Category: Hematology Authors: Nelli Bejanyan Source Type: research

Masthead (Purpose and Scope)
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 17, 2017 Category: Hematology Source Type: research

Editorial Board
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 17, 2017 Category: Hematology Source Type: research

Officers and Directors of ASBMT
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 17, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 17, 2017 Category: Hematology Source Type: research

In Memoriam: Hanna Jean Khoury, MD (April 24, 1967, to May 22, 2017)
The great American author and political cartoonist Dr Theodor Seuss Geisel, known best as Dr Seuss, a name which he adopted during his early creative years at Dartmouth College in 1927, wrote about the death of a dear friend of his: “Don't cry because it's over…smile because it happened.” (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 17, 2017 Category: Hematology Authors: John F. DiPersio Source Type: research

ASBMT Notes
The field of hematopoietic cell transplantation (HCT) has grown increasingly complex with expanding applications and donor options. A major component of a successful transplantation outcome is appropriate and timely referral of patients for consultation. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 17, 2017 Category: Hematology Source Type: research

Consensus Report by the Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplant Consortium Joint Working Committees on Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents: Part 2 —Focus on Ascites, Fluid and Electrolytes, Renal, and Transfusion Issues
Veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a potentially fatal complication associated with hematopoietic stem cell transplatation (HCT) [1-4]. The reported heterogeneity in the management of children with VOD is likely related to the dearth of published evidence [5-11]. Conducting appropriately powered randomized controlled trials in the pediatric cohort is logistically challenging; thus, extrapolation from indirect evidence is often the best means of guiding management. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - August 17, 2017 Category: Hematology Authors: Kris M. Mahadeo, Jennifer McArthur, Roberta H. Adams, Mohamed Radhi, Joseph Angelo, Asumthia Jeyapalan, Kathleen Nicol, Leon Su, Hanna Rabi, Jeffery J. Auletta, Vinita Pai, Christine N. Duncan, Robert Tamburro, Christopher C. Dvorak, Rajinder P.S. Bajwa Source Type: research

Consensus Report by PALISI and PBMTC Joint Working Committees, Supportive Care Guidelines for Management of VOD in Children and Adolescents: Part 2 - Focus on Ascites; Fluids, Electrolytes, Renal and Transfusion Issues.
This report highlights the importance of fluid, electrolytes and renal dysfunction in the management of VOD, and gives a time line for renal replacement therapy initiation.• The strategies for prevention, diagnosis and management of fluid overload are discussed• The management of peritoneal and pleural effusion is discussed along with abdominal compartment syndrome and strategies to avoid paracentesis-induced circulatory dysfunction.• Indications for blood and platelets transfusion are presented, along with the role of TEG / ROTEM in the management of VOD• Approach to a VOD patient with acute bleeding i...
Source: Biology of Blood and Marrow Transplantation - August 17, 2017 Category: Hematology Authors: Kris M Mahadeo, Jennifer McArthur, Roberta H. Adams, Mohamed Radhi, Joseph Angelo, Asumthia Jeyapalan, Kathleen Nicol, Leon Su, Hanna Rabi, Jeffery J Auletta, Vinita Pai, Christine N Duncan, Robert Tamburro, Christopher C Dvorak, Rajinder PS Bajwa Source Type: research